C12N2320/13

Methods and compositions for selecting siRNA of improved functionality

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for AAT.

Methods and Compositions for Selecting siRNA of Improved Functionality

Efficient sequence specific gene silencing is possible through the use of siRNA technology. Be selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to the nucleotide sequences for F12.

METHODS AND COMPOSITIONS FOR RAPID DIRECT DETECTION AND DIFFERENTIATION OF INFECTIOUS FROM NONINFECTIOUS VIRUS

Methods of detecting presence of a virus in a sample are provided, the method including contacting the sample with a solid state nanopore comprising a plurality of virus-specific aptamers and measuring a current-voltage curve in the solid state nanopore, wherein a decrease in the current indicates presence of the virus in the sample. Solid state nanopores comprising a plurality of virus-specific aptamers covalently linked to the interior of the solid state nanopore are also provided. Membranes including a plurality of solid state nanopores including a plurality of covalently attached virus-specific aptamers and kits and systems with a membrane including a plurality of solid state nanopores including a plurality of covalently attached virus-specific aptamers are also provided.

Aptamers and use of the aptamers in the diagnosis and treatment of cancer

The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumors.

APTAMER AGAINST IRINOTECAN

The present invention relates inter alia to aptamers that specifically bind to Irinotecan and methods of using the same.

Compositions and methods relating to synthetic RNA polynucleotides created from synthetic DNA oligonucleotides

Compositions and methods are provided for forming a single RNA polynucleotide from a plurality of DNA oligonucleotides in a single reaction chamber using combined reagents in a single step reaction. DNA polymerase, RNA polymerase and single stranded (ss) DNA oligonucleotides are combined where each DNA oligonucleotide has one or more sequence modules, wherein one sequence module in the first ss DNA oligonucleotide is complementary to a sequence module at the 3′ end of the second ss DNA oligonucleotide; and wherein a second module on the first ss DNA oligonucleotide is an RNA polymerase promoter sequence; and forming a single RNA polynucleotide, excluding the RNA promoter sequence, derived from the first and second DNA oligonucleotides

Aptamers Against Clostridium Difficile

Compositions comprising aptamers capable of specifically binding to a surface protein of Clostridium difficile spore are provided. A method for detecting, enriching, separating, and/or isolating Clostridium difficile spores is provided.

FUNCTIONAL LIGANDS TO NERVE AGENT METABOLITES
20170233738 · 2017-08-17 ·

This invention relates to functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, more particularly to functional ligands with binding affinity to metabolites of nerve agents, and further particularly to functional ligands with binding affinity to metabolites of VX-acid (metabolite of VX nerve agent) and GB-acid (metabolite of sarin nerve agent).

Functional ligands to drug compounds

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as drug compounds, such as levamisole and cocaine.

GOLD NANOPARTICLE-SELEX BASED SCREENING METHOD FOR TARGET-SPECIFIC APTAMERS

Systematic Evolution of Ligand Exponential Enrichment (SELEX) is involved to screen DNA/RNA aptamers that recognize a target molecule (including biomolecules such as nucleic acids, lipids, sugars, proteins, and peptides, hormones, low molecular weight chemical substances, toxic substances, ions, etc.). In general, in order to perform SELEX, a process of fixing a target molecule on a substrate or bead surface is required. In addition, since positive/negative monitoring is not possible in each round of a SELEX process to observe whether an aptamer library is actually well combined with a target substance, whether the SELEX process is proceeded correctly is checked by analyzing aptamers screened through several rounds. In order to remarkably solve these conventional problems and to construct a simpler and easier SELEX technique, the present disclosure provides a new SELEX technique using gold nanoparticles.